BCRX
BioCryst Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-22/100
Last price
7.94
▼ 0.16 (1.98%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
8.06
Prev close
8.10
Day high
8.15
Day low
7.87
Volume
3.94M
Market cap
$2.03B
P/E (TTM)
—
52W range
6.00 – 11.22
Day trading desk
Gap from prior close
-0.49%
Prior close 8.10
VWAP
7.97
-0.32% from price
Relative volume
1.29×
Normal
Session range
8.28%
7.85 – 8.50
Position in range
14%
Near session low
ATR (14D)
0.30
3.74% of price
Prior day high
8.25
PDH
Prior day low
7.92
PDL
Bid / ask spread
—
Quote not published
Session volume
5.36M
Avg 4.15M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.87%
-5.8%
1M
-20.18%
-21.3%
3M
-28.44%
-33.0%
6M
-17.10%
-35.3%
YTD
+1.92%
-12.3%
1Y
+11.19%
-5.2%
3Y
+12.29%
-70.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BCRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+136.40K
Net buying
Buy transactions
20
210.08K shares
Sell transactions
2
73.68K shares
Net transactions
+22
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
3.26M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 31, 26 | MILANO VINCENT J Director |
STOCK | 1.16K | $11.24K | Direct |
| Aug 31, 26 | MILNE JILL C. PH.D. Director |
STOCK | 1.29K | $12.49K | Direct |
| Aug 31, 26 | MCKEE AMY E Director |
STOCK | 644 | $6.25K | Direct |
| Aug 31, 26 | STONEHOUSE JON P Director |
STOCK | 644 | $6.25K | Direct |
| Aug 31, 26 | FRANK STEVEN R Director |
STOCK | 1.29K | $12.49K | Direct |
| Jun 11, 26 | MILANO VINCENT J Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | LEVIN ALAN G Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | MILNE JILL C. PH.D. Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | SANDERS MACHELLE Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | HEGGIE THERESA Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | MCKEE AMY E Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | STONEHOUSE JON P Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | GALSON STEVEN K Director |
STOCK | 15.29K | $0 | Direct |
| Jun 11, 26 | FRANK STEVEN R Director |
STOCK | 15.29K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARNES ALANE P |
Officer | 400.70K | Sale |
DOYLE ANTHONY |
Chief Financial Officer | 377.87K | Stock Award(Grant) |
GALSON STEVEN K |
Director | 86.17K | Stock Award(Grant) |
GAYER CHARLES K |
President | 952.58K | Conversion of Exercise of derivative security |
GHIAS BABAR |
Chief Financial Officer | 268.70K | Stock Award(Grant) |
HUTSON NANCY J |
Director | 99.14K | Stock Award(Grant) |
MENON SANDEEP |
Officer | 205.15K | Stock Award(Grant) |
MILANO VINCENT J |
Director | 109.64K | Stock Award(Grant) |
STONEHOUSE JON P |
Director | 1.42M | Stock Award(Grant) |
THACKRAY HELEN M |
Officer | 384.84K | Stock Award(Grant) |
Fundamentals
Market cap$2.03B
Enterprise value$2.52B
Revenue (TTM)$940.61M
Gross profit$727.92M
EBITDA$433.05M
Net income$-384.67M
EPS (TTM)$-1.40
Free cash flow$323.67M
Total cash$352.57M
Total debt$836.64M
Book value / share$-1.78
Shares outstanding255.54M
Float222.32M
Short % of float13.75%
Dividend yield0.00%
Beta (5Y)0.55
Valuation & profitability ratios
Trailing P/E—
Forward P/E8.46
PEG ratio9.39
Price / sales—
Price / book—
EV / revenue2.67
EV / EBITDA5.81
Gross margin77.39%
Operating margin45.12%
Profit margin-40.90%
Return on equity—
Return on assets52.86%
Debt / equity—
Current ratio2.32
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $874.84M | $450.71M | $331.41M | $270.83M | +94.1% |
| Operating revenue | $874.84M | $450.71M | $331.41M | $270.83M | +94.1% |
| Cost of revenue | $19.07M | $12.27M | $4.48M | $6.59M | +55.5% |
| Gross profit | $855.76M | $438.44M | $326.93M | $264.23M | +95.2% |
| Research & development | $166.13M | $174.64M | $216.57M | $253.30M | -4.9% |
| Selling, general & admin | $348.65M | $266.35M | $214.07M | $159.37M | +30.9% |
| Total operating expense | $514.77M | $440.99M | $430.64M | $412.67M | +16.7% |
| Operating income | $340.99M | -$2.54M | -$103.71M | -$148.44M | +13,508.9% |
| Net interest income | -$68.20M | -$83.77M | -$92.46M | -$93.97M | +18.6% |
| Pre-tax income | $267.39M | -$86.95M | -$226.23M | -$244.38M | +407.5% |
| Tax provision | $3.53M | $1.93M | $310.00K | $2.73M | +83.2% |
| Net income | $263.86M | -$88.88M | -$226.54M | -$247.12M | +396.9% |
| Net income to common | $263.86M | -$88.88M | -$226.54M | -$247.12M | +396.9% |
| Basic EPS | 1.26 | -0.43 | -1.18 | -1.33 | +393.0% |
| Diluted EPS | 1.21 | -0.43 | -1.18 | -1.33 | +381.4% |
| EBIT | $346.26M | $11.56M | -$117.99M | -$145.29M | +2,894.8% |
| EBITDA | $347.65M | $12.81M | -$116.33M | -$143.85M | +2,614.3% |
| Basic shares | 209.89M | 206.70M | 192.20M | 185.91M | +1.5% |
| Diluted shares | 218.58M | 206.70M | 192.20M | 185.91M | +5.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $89.74M | $104.71M | $110.64M | $304.77M | -14.3% |
| Cash & short-term investments | $274.75M | $320.85M | $388.99M | $424.31M | -14.4% |
| Accounts receivable | $106.82M | $79.07M | $56.95M | $50.60M | +35.1% |
| Inventory | $5.40M | $8.09M | $28.68M | $27.53M | -33.3% |
| Total current assets | $404.35M | $421.97M | $495.97M | $516.50M | -4.2% |
| Property, plant & equipment | $18.99M | $19.79M | $20.91M | $8.62M | -4.0% |
| Total assets | $514.16M | $490.42M | $516.96M | $550.00M | +4.8% |
| Total current liabilities | $196.07M | $160.38M | $149.99M | $105.51M | +22.2% |
| Long-term debt | $427.23M | $795.92M | $811.26M | $733.28M | -46.3% |
| Total debt | $438.87M | $808.74M | $825.15M | $741.45M | -45.7% |
| Total liabilities | $633.31M | $966.35M | $972.49M | $844.60M | -34.5% |
| Retained earnings | -$1.51B | -$1.77B | -$1.68B | -$1.45B | +14.9% |
| Shareholder equity | -$119.15M | -$475.93M | -$455.53M | -$294.60M | +75.0% |
| Working capital | $208.28M | $261.58M | $345.98M | $410.99M | -20.4% |
| Net tangible assets | -$119.15M | -$475.93M | -$455.53M | -$294.60M | +75.0% |
| Shares issued | 213.06M | 208.54M | 205.77M | 187.91M | +2.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $263.86M | -$88.88M | -$226.54M | -$247.12M | +396.9% |
| Depreciation & amortisation | $1.39M | $1.25M | $1.66M | $1.44M | +11.5% |
| Stock-based compensation | $85.07M | $65.41M | $55.62M | $44.70M | +30.0% |
| Change in working capital | -$56.90M | -$87.28M | -$32.40M | -$58.95M | +34.8% |
| Operating cash flow | $347.37M | -$52.02M | -$95.14M | -$161.85M | +767.8% |
| Capital expenditure | -$2.47M | -$1.12M | -$2.17M | -$1.35M | -119.6% |
| Investing cash flow | -$13.69M | $52.59M | -$131.50M | -$128.24M | -126.0% |
| Financing cash flow | -$349.93M | -$5.76M | $32.48M | $88.03M | -5,974.1% |
| Free cash flow | $344.90M | -$53.14M | -$97.31M | -$163.20M | +749.0% |
| End cash position | $91.34M | $106.32M | $112.45M | $306.24M | -14.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $218.25M | $156.41M | $406.56M | $159.40M | $163.35M | +39.5% |
| Operating revenue | $157.51M | $151.36M | $406.56M | $159.40M | $162.43M | +4.1% |
| Cost of revenue | $3.84M | $5.38M | $9.52M | $2.19M | $2.80M | -28.6% |
| Gross profit | $214.41M | $151.04M | $397.03M | $157.21M | $160.56M | +42.0% |
| Research & development | $51.97M | $758.08M | $40.87M | $44.60M | $43.39M | -93.1% |
| Selling, general & admin | $63.98M | $94.55M | $95.78M | $83.01M | $87.38M | -32.3% |
| Total operating expense | $115.94M | $852.63M | $136.65M | $127.62M | $130.77M | -86.4% |
| Operating income | $98.47M | -$701.60M | $260.38M | $29.59M | $29.79M | +114.0% |
| Net interest income | -$19.28M | -$17.52M | -$11.24M | -$17.42M | -$19.07M | -10.0% |
| Pre-tax income | $79.47M | -$720.81M | $248.02M | $12.13M | $6.49M | +111.0% |
| Tax provision | $1.08M | $1.00M | $2.17M | -$769.00K | $1.40M | +7.5% |
| Net income | $78.39M | -$721.81M | $245.84M | $12.90M | $5.08M | +110.9% |
| Net income to common | $78.39M | -$721.81M | $245.84M | $12.90M | $5.08M | +110.9% |
| Basic EPS | 0.31 | -2.98 | 1.17 | 0.06 | 0.02 | +110.4% |
| Diluted EPS | 0.30 | -2.98 | 1.12 | 0.06 | 0.02 | +110.1% |
| EBIT | $101.19M | -$701.03M | $262.15M | $31.79M | $28.07M | +114.4% |
| EBITDA | $101.70M | -$700.57M | $262.55M | $32.13M | $28.40M | +114.5% |
| Basic shares | 254.48M | 242.26M | 210.97M | 210.18M | 209.52M | +5.0% |
| Diluted shares | 265.17M | 242.26M | 219.26M | 219.88M | 219.89M | +9.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $154.97M | $171.59M | $89.74M | $84.08M | $88.03M | -9.7% |
| Cash & short-term investments | $352.57M | $238.40M | $274.75M | $212.87M | $260.04M | +47.9% |
| Accounts receivable | $110.76M | $109.27M | $106.82M | $91.33M | $91.18M | +1.4% |
| Inventory | $6.06M | $5.99M | $5.40M | $5.23M | $5.04M | +1.2% |
| Total current assets | $484.68M | $373.63M | $404.35M | $355.68M | $398.46M | +29.7% |
| Property, plant & equipment | $21.67M | $22.98M | $18.99M | $19.24M | $20.00M | -5.7% |
| Total assets | $557.85M | $465.05M | $514.16M | $446.42M | $457.19M | +20.0% |
| Total current liabilities | $208.85M | $195.39M | $196.07M | $190.24M | $177.16M | +6.9% |
| Long-term debt | $778.38M | $802.38M | $427.23M | $633.47M | $690.64M | -3.0% |
| Total debt | $792.84M | $817.77M | $438.87M | $645.42M | $703.18M | -3.0% |
| Total liabilities | $1.01B | $1.02B | $633.31M | $834.31M | $878.78M | -0.7% |
| Retained earnings | -$2.15B | -$2.23B | -$1.51B | -$1.75B | -$1.76B | +3.5% |
| Shareholder equity | -$454.29M | -$553.84M | -$119.15M | -$387.89M | -$421.59M | +18.0% |
| Working capital | $275.84M | $178.23M | $208.28M | $165.45M | $221.30M | +54.8% |
| Net tangible assets | -$454.29M | -$553.84M | -$119.15M | -$387.89M | -$421.59M | +18.0% |
| Shares issued | 255.26M | 254.01M | 213.06M | 210.52M | 209.91M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $78.39M | -$721.81M | $245.84M | $12.90M | $5.08M | +110.9% |
| Depreciation & amortisation | $513.00K | $461.00K | $394.00K | $335.00K | $329.00K | +11.3% |
| Stock-based compensation | $14.69M | $16.03M | $23.79M | $18.60M | $21.30M | -8.3% |
| Change in working capital | -$3.11M | -$71.40M | $4.23M | -$1.37M | $2.38M | +95.6% |
| Operating cash flow | $104.34M | -$61.79M | $291.96M | $41.62M | $41.30M | +268.9% |
| Capital expenditure | -$209.00K | -$403.00K | -$802.00K | -$1.34M | -$179.00K | +48.1% |
| Investing cash flow | -$110.15M | -$268.65M | -$83.49M | $13.57M | $29.13M | +59.0% |
| Financing cash flow | -$11.15M | $412.55M | -$217.96M | -$58.81M | -$73.69M | -102.7% |
| Free cash flow | $104.13M | -$62.19M | $291.16M | $40.28M | $41.12M | +267.4% |
| End cash position | $156.38M | $173.38M | $91.34M | $86.06M | $89.92M | -9.8% |
Options analytics
Put / call volume
0.27
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
6.00
-24.5% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
435
Contracts, this expiry
Put volume
117
Contracts, this expiry
Heaviest call OI
6.00
0 contracts
Heaviest put OI
6.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.24 | 0.35 | +49.4% |
| Mar 2026 | 0.11 | 0.14 | +27.7% |
| Dec 2025 | 0.07 | 0.21 | +197.6% |
| Sep 2025 | 0.07 | 0.16 | +125.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.12 | 2 | $165.68M | +3.9% |
| Next quarter | 0.13 | 2 | $169.77M | -58.2% |
| Current year | 0.75 | 2 | $710.08M | -18.8% |
| Next year | 0.94 | 2 | $738.66M | +4.0% |
Analyst targets & ownership
Mean target$20.73
High target$32.00
Low target$11.00
Implied upside161.05%
Analyst count11
ConsensusBUY
Strong buy / Buy2 / 7
Hold2
Sell / Strong sell0 / 0
Held by insiders1.28%
Held by institutions105.31%
Institutions holding418
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
8.31
-4.44% from price
SMA 20
8.40
-5.39% from price
SMA 50
9.17
-13.27% from price
SMA 100
9.20
-13.72% from price
SMA 200
8.69
-8.50% from price
EMA 12
8.32
-4.61% from price
EMA 26
8.65
-8.16% from price
EMA 50
8.94
-11.14% from price
RSI (14)
32.4
Neutral
MACD (12,26,9)
-0.32
Hist -0.02
ATR (14)
0.30
3.74% of price
Realised vol 30D
40.2%
Annualised
Bollinger upper
8.92
20, 2σ
Bollinger lower
7.89
20, 2σ
50 / 200 cross
Golden
9.17 vs 8.69
Trend bias
Below 200
-8.50%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.63
Less volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
40.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-28.4%
Peak to trough
Max drawdown 5Y
-79.1%
Peak to trough
ATR 14
0.30
3.74% of price
Beta (reported)
0.55
5Y monthly, from filing
Short interest
Shares short
34.87M
Prior 32.94M
Change vs prior
+5.9%
Shorts adding
% of float
13.75%
Elevated
% of shares out
13.65%
Against total outstanding
Days to cover
9.8
Crowded exit
Float
222.32M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Sep 10, 26 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| Sep 8, 26 | Needham | MAINTAINED | Buy | Buy |
| Aug 6, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jun 30, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 30, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| May 7, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| May 7, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 6, 26 | Needham | MAINTAINED | Buy | Buy |
| Jan 30, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K/A · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-29
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-05-06
Corporate Changes & Voting Matters
8-K · 2026-05-04
Annual Report to Shareholders
ARS · 2026-04-23
Periodic Financial Reports
10-K · 2026-02-26
Headlines
BioCryst Pharmaceuticals Forms Scientific Advisory Board as R&D Model Evolves
MT Newswires · 2d ago
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
GlobeNewswire · 2d ago
Claude AI Just Bought These 2 Pharma Stocks
Insider Monkey · 8d ago
Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?
Insider Monkey · 14d ago
Biopharma Stock With Layers of Technical Support in Place
Schaeffer's Investment Research · 15d ago
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
MarketBeat · 18d ago
4 Biotech Stocks to Watch as Potential Takeover Targets
Zacks · 19d ago
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs
Insider Monkey · 20d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.